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The intrinsic propensity of 1-antitrypsin to undergo conformational transitions
from its metastable native state to hyperstable forms provides a motive force for
its antiprotease function. However, aberrant conformational change can also
occur via an intermolecular linkage that results in polymerization. This has both
loss-of-function and gain-of-function effects that lead to deficiency of the
protein in human circulation, emphysema and hepatic cirrhosis. One of the most
promising therapeutic strategies being developed to treat this disease targets
small molecules to an allosteric site in the 1-antitrypsin molecule. Partial filling
of this site impedes polymerization without abolishing function. Drug
development can be improved by optimizing data on the structure and
dynamics of this site. A new 1.8 A˚ resolution structure of 1-antitrypsin
demonstrates structural variability within this site, with associated fluctuations in
its upper and lower entrance grooves and ligand-binding characteristics around
the innermost stable enclosed hydrophobic recess. These data will allow a
broader selection of chemotypes and derivatives to be tested in silico and in vitro
when screening and developing compounds to modulate conformational change
to block the pathological mechanism while preserving function.
1. Introduction
1-Antitrypsin is the most abundant antiprotease in the human
circulation (Heimburger & Haupt, 1965). It is also the archetypal
member of the serpin (serine protease inhibitor) superfamily of
proteins (Silverman et al., 2001). Serpins are characterized by a
metastable native fold consisting of nine -helices (A–I) and three
-pleated sheets (A–C). A propensity to undergo stabilizing confor-
mational change involving expansion of -sheet A is utilized in the
structural transitions required for protease inhibition (Huntington
et al., 2000). However, pathological point mutations trigger aberrant
opening of -sheet A, allowing serpins to homopolymerize via
exchange of complementary stabilizing motifs between neighbouring
molecules (Gooptu & Lomas, 2009). Polymerization of 1-antitrypsin
results in emphysema and hepatic cirrhosis, as well as circulating
deficiency, through gain-of-function and loss-of-function effects
(Gooptu & Lomas, 2008).
Polymerization may be blocked directly by annealing reactive-loop
analogue peptides to the central loop insertion site (s4A) in -sheetA
(Chang et al., 2011; Lomas et al., 1992). However, this approach also
abolishes functional inhibitory activity and faces technical challenges
in drug development. A promising alternative strategy blocks poly-
merization by targeting an allosteric site, a cavity flanking -sheet A
that is sealed during loop insertion (Parfrey et al., 2003; Gooptu et al.,
2009; Fig. 1). Mutagenesis studies show that partial occupation of this
site can impede polymerization and preserve the inhibitory function
of 1-antitrypsin. Lead molecules targeted to fully occupy this site
block polymerization but, as with s4A-binding peptides, abolish
inhibitory function (Mallya et al., 2007). There is therefore a need to
develop smaller molecules that mimic the effects of a space-filling
mutation more faithfully. Reducing the size of screened moieties to
the ‘fragment’ range (<250 Da) may help identify promising initial
hits, but at the expense of binding affinity and specificity. To develop
hits into well targeted molecules will therefore require their modifi-
cation, via derivatives that ‘grow’ the molecule based upon what is
known about the binding site. The process will be aided by as much
high-resolution data and dynamic information as possible. We have
now solved the highest resolution (1.8 A˚) crystal structure of 1-
antitrypsin. The increased detail provides insight into the mechanism
of -sheet A expansion by delineating the hydration of a relatively
hydrophobic environment around the highly conserved Trp194
residue, rendering the initial loop insertion site conformationally
labile. These data nicely explain findings from previous tryptophan
fluorescence studies of conformational change during polymeriza-
tion. Moreover, comparison with 2.0 A˚ resolution structures char-
acterizes variation in the conformational dynamics of the allosteric
pocket in solution. This demonstrates that the allosteric site is likely
to be one of the most variable environments around the 1-anti-
trypsin molecule and will aid future drug targeting to this feature.
2. Methods
pQE31 plasmid containing cDNA encoding hexahistidine-tagged
recombinant wild-type 1-antitrypsin was transfected into XL1 Blue
Escherichia coli cells (Stratagene). The proteins were expressed and
purified as described previously (Parfrey et al., 2003). They were
characterized using SDS–PAGE, nondenaturing PAGE and trans-
verse urea gradient (TUG) PAGE, circular-dichroism (CD) spectro-
scopy and enzyme-inhibitory activity and kinetics assays (Dafforn et
al., 2004; Stone & Hofsteenge, 1986).
Crystals of 1-antitrypsin were grown in 0.1M MMT buffer (1:2:2
dl-malic acid:MES:Tris base) pH 6.0, 20%(w/v) PEG 1500, 330 mM
N-{4-hydroxy-3-methyl-5-[(1H-1,2,4,5-tetrazol-3-yl)sulfanyl]phenyl}-
4-methylbenzenesulfonamide by hanging-drop vapour diffusion at
293 K. These crystals were then loop-mounted and cryocooled in
cryoprotectant buffer [0.1M MMT pH 6.0, 20%(w/v) PEG 1500,
20%(v/v) glycerol]. Synchrotron diffraction data were collected on
beamline 23.1 at the ESRF, Grenoble, France. Processing of the X-ray
diffraction data was performed using iMOSFLM (Battye et al., 2011)
and SCALA (Evans, 2006). The structure of 1-antitrypsin was solved
by molecular replacement with Phaser (McCoy et al., 2007) to a
resolution of 1.8 A˚ using the coordinates of the native 1-antitrypsin
crystal structure (PDB entry 1qlp; Elliott et al., 2000) as a search
model. An initial model was constructed using Coot (Emsley &
Cowtan, 2004) and the structure was refined using REFMAC5
(Murshudov et al., 2011). Iterative cycles of model building and
refinement were carried out until the R factors stabilized. The
stereochemistry of the final model (PDB entry 3ne4) was checked
using PROCHECK (Laskowski et al., 1993).
The cavity flanking -sheet A in the new structure was assessed
and compared with those observed in the two structures of nearest
resolution (PDB entries 1qlp and 2qug; Pearce et al., 2008) using the
program SiteMap 2.5 and other programs from the Schro¨dinger suite
(Schro¨dinger LLP, New York, USA). The crystal structures were
prepared using the Protein Preparation Wizard protocol in the
Maestro program. Ligands, waters and other cocrystallized agents
were deleted and H atoms were added. The protassign script was used
to optimize intramolecular contacts. The impref script was used to
perform restrained minimization of the protein (default settings in
Maestro v.9.2). All structures were superposed using the structalign
utility from Schro¨dinger. A site was defined as an enclosed region
comprising at least 15 site points (default settings in SiteMap v.2.5).
SiteMap uses an algorithm to identify and characterize favourable
sites in a protein structure for drug binding. Probe-based and energy-
based methods are used to estimate the interaction energy between
probe and protein along a three-dimensional grid that samples the
space around the structural model. These values are combined with
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Figure 1
Lateral movement (arrow) of -strands during 1-antitrypsin polymerization and a
strategy for blockade via targeting of an allosteric site (ellipse) lateral to -sheet A
(blue). Expansion of the -sheet to accommodate an extra -strand derived from
the reactive loop (red) fills this site. In this figure, the structure of native 1-
antitrypsin (PDB entry 1qlp) is depicted using PyMOL (DeLano, 2002) cartoon
settings.
Table 1
X-ray data-collection and processing statistics for the native wild-type 1-
antitrypsin crystal structure 3ne4.
Values in parentheses are for the highest resolution shell.
Space group C2
Unit-cell parameters (A˚, ) a = 114.4, b = 38.9, c = 88.8,
 = 104.3
Resolution (A˚) 42.11–1.81 (1.91–1.81)
No. of reflections
Total 92961
Unique 34169
Rmerge† 0.07 (0.274)
Completeness (%) 98.5 (99.1)
Multiplicity 2.7 (2.6)
hI/(I)i 10.0 (3.4)
Rcryst‡ (%) 18.7
Rfree§ (%) 23.3
Bave} (A˚
2)
Main chain 23.9
Side chain 28.8
No. of water molecules 217
Ramachandran plot, residues in (%)
Preferred region 96.5
Allowed region 3.3
Disallowed region 0.3
R.m.s.d. from ideal
Bond lengths (A˚) 0.015
Bond angles () 1.5
† Rmerge =
P
hkl
P
i jIiðhklÞ  hIðhklÞij=
P
hkl
P
i IiðhklÞ, where i are the set of observa-
tions for each reflection hkl. ‡ Rcryst =
P
hkl

jFobsj  jFcalcj

=
P
hkl jFobsj. § Rfree =
Rcryst for 5% of reflections omitted from refinement. } Bave values are average
temperature factors for all molecules in the asymmetric unit.
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Figure 2
(a) 1.8 A˚ resolution crystal structure of 1-antitrypsin (PDB entry 3ne4) with -helices and -strands labelled (e.g. helix A, hA; strand 1 of -sheet A, s1A). Strands within a
-sheet are colour-coded together (A, blue; B, bronze; C, green). Detail is shown for the following. Box I, the reactive centre of the molecule in the canonical conformation.
Box II, the ‘breach’ position that is the site of initial intramolecular loop insertion during monomeric conformational transitions. Box III, the fit of the hD–s2A turn. The
upper panel shows the rigid fit of 1qlp (gold) together with the initial OMIT map (Fo  Fc at 3 density when residues 105–110 are omitted; positive difference density in
green, negative in red). The lower panel shows the final fit of 3ne4 (orange) to the final map (blue, 2Fo  Fc at 1 density). (b) R.m.s.d. for observed 1-antitrypsin residues in
3ne4 compared with 1qlp (upper panel) and 2qug (lower panel) calculated using the SUPERPOSE program from the CCP4 suite (Winn et al., 2011). (c) Comparison of B
factors in 1qlp (above) and 3ne4 (below). Low/high values are indicated by rainbow-spectrum colouring by PyMOL using a preset scale (blue for low to red for high). Whilst
overall B factors are lower in 3ne4 (range 9.60–83.99 A˚2, mean 23.9 A˚2) than 1qlp (range 13.82–96.92 A˚2, mean 38.4 A˚2), the hD–s2A turn is associated with increased values
in both relative to the global values. Other regions that show relative increases in B factor are the C-terminal end of helixA and the upper turn of helix F, which is believed to
be dynamic in solution and to remodel during formation of the intermediate.
geometry terms to give a druggability scoring function that is a
function of volume and site enclosure (solvent exclusion). A penalty
factor is calculated for hydrophilicity. Other parameters that are
calculated for each site are volume, solvent exposure, contacts,
hydrophobicity and hydrogen-donor/acceptor sites.
3. Results and discussion
We have determined the highest resolution (1.8 A˚) crystallographic
structure of native 1-antitrypsin solved to date (PDB entry 3ne4;
Fig. 2a). Refinement statistics are listed in Table 1. As expected,
its overall fold and the positioning of secondary-structure elements
are highly similar to the previous 2.0 A˚ resolution structure (Elliott
et al., 2000; PDB entry 1qlp; C r.m.s.d. 0.3 A˚; Fig. 2b). However, the
higher resolution is associated with a reduction in B factors overall
(Fig. 2c) and improves confidence in details such as the positioning of
side-chain atoms and water molecules.
Occupancy of alternative rotameric orientations for Val216 and
Ile340 became apparent during refinement. These are found on
-strand s4C and in the hinge region between -strand s5A and the
reactive loop. Coordination of the canonical inhibitory conformation
at the reactive centre of the molecule by a water molecule between
the side chain of Ser283 and the main-chain carbonyls of the P2 and
P10 residues is confirmed in the new structure (Fig. 2a, box I). This
water is observed in only one (PDB entry 1qlp) of the 2.0 A˚
structural communications
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Figure 3
SiteMap analysis of the cavity flanking -sheet A in 1qlp (left), 2qug (centre) and 3ne4 (right). The cavities are shown as identified by SiteMap in a surface representation
(top). The total surface (grey) is shown above the component parts that can participate in ligand binding through hydrophobic interactions (yellow), via hydrogen-bond
acceptance (red) or via hydrogen-bond donation (blue). Green dashed lines demarcate dynamic channel topologies implied by the three structures.
resolution crystal structures of native 1-antitrypsin solved
previously. In the other case (PDB entry 2qug; Pearce et al., 2008),
similarly to the 2.1 A˚ resolution structure (PDB entry 1hp7; Kim et
al., 2001), this water is not seen and the canonical conformation of
these residues is distorted. Accordingly, the r.m.s.d. is greater for 3ne4
and 2qug across the reactive-loop residues (340–362) than between
3ne4 and 1qlp (Fig. 2b). Moreover, the solvation environment
between Trp194 and the plane of -sheet A is clearly seen to involve
three water molecules (numbered 7, 49 and 54) whose centroids lie
within 3–5 A˚ of the Trp side chain (Fig. 2a, box II). They are co-
ordinated by nearby main-chain carbonyl O atoms. This is of interest
since changes around Trp194 are reported by changes in intrinsic
fluorescence spectrometry of 1-antitrypsin. It is therefore commonly
used as a reporter residue for conformational change involving
rearrangements around its position underlying the top of -sheet A
(Dafforn et al., 1999; Tew & Bottomley, 2001). High-resolution
structures of latent (Im et al., 2002) and cleaved (Yamasaki et al.,
2010) 1-antitrypsin clearly show the exclusion of solvent in this
region. Previous structures of native wild-type 1-antitrypsin (Elliott
et al., 2000; Pearce et al., 2008) have indicated the presence of zero,
one or two waters in this region. In 3ne4 one of the three water
molecules hydrogen bonds to the carbonyl O atom of Thr339. This
interaction prevents the formation of a typical interstrand hydrogen
bond between the carbonyl of residue Thr339 at the top of s5A and
Gly192 at the top of s3A. It therefore facilitates the opening of the
upper s4A insertion site, which necessitates separation of these
residues at the top of s3A and s5A. The upper s4A site superficially
appears to be less accessible to reactive-loop or peptide annealing in
1-antitrypsin compared with other native serpins. However, this
finding shows how initial insertion of a residue in this ‘P14 position’
(Schechter and Berger notation; Schechter & Berger, 1967) does not
come at the cost of breaking an interstrand hydrogen bond in
1-antitrypsin.
Fascinatingly, the intrinsic fluorescence spectrum of 1-antitrypsin
reports the formation of both the intermediate and polymer during
polymerization by a small blue shift and increased intensity attribu-
table to Trp194 (Dafforn et al., 1999). This is consistent with increased
solvent exclusion, since increased solvent exposure of this residue is
reported instead by a large red shift and no change in maximal
intensity (Tew & Bottomley, 2001). If formation of the monomeric
intermediate were associated with simple opening of the upper s4A
site, exposing Trp194 to a bulk-solvent environment, it should
predictably be reported by a red shift and unchanged intensity. This
would presumably apply even more if the intermediate were sub-
stantially unfolded, as recently proposed (Yamasaki et al., 2008).
However, these findings may be explained if intermediate formation
is instead associated with a decrease in the local solvation of Trp194,
e.g. by filling of the upper s4A site to exclude the three water
molecules, as previously modelled (Gooptu et al., 2000, 2009). Thus,
changes in this solvation state are likely to be intimately connected
with conformational change in 1-antitrypsin, consistent with the
sensitivity of Trp194 as a reporter moiety.
3.1. Conformational variability in the cavity flanking b-sheet A
The most significant difference in main-chain conformation
between the new structure and the search model 1qlp occurs at
the hD–s2A turn (residues 105–110, Fig. 2b) that forms the upper
boundary of the hydrophobic pocket targeted for allosteric
polymerization blockade (Fig. 1; Mallya et al., 2007). This region is
typically less well ordered than the overall fold in crystal structures of
many native serpins, including 1-antitrypsin. The improved resolu-
tion obtained in the current study aided confident fitting into
observed density through use of an OMIT map (Fig. 2a, box III).
The hD–s2A region is associated with relatively low B factors in
latent (Im et al., 2002) and cleaved (Yamasaki et al., 2010) species in
which the cavity is filled, but high B factors relative to other regions
in crystal structures of native 1-antitrypsin. Despite this and the
differences observed here between the 1qlp and 3ne4 structures, they
are both based upon data to high resolution and have good enough
bond geometries to be reasonably confident of the accuracy of model
building in each case. Moreover, the turn is not near lattice contacts
in either structure. The differences between 1qlp and 3ne4 are
therefore likely to reflect alternative conformations of this region that
are involved in conformational exchange.
We examined variability in the allosteric cavity flanking -sheet
A by SiteMap analysis of high-resolution structures: 1qlp (which was
first used to define it; Elliott et al., 2000), 2qug (Pearce et al., 2008),
another 2.0 A˚ resolution crystal structure of native 1-antitrypsin,
and 3ne4 (Fig. 3). In addition to the variability in the hD–s2A turn
region, the major differences observed between the cavity in 1qlp
and 3ne4 are the topology at its upper and lower poles and, where
topology is conserved, in the hydrogen-bond acceptor characteristics
(Fig. 3, red). The hD–s2A turn movement observed in 3ne4 relative to
1qlp abolishes an upper recess within the cavity in the latter structure
(top left panel, green ellipse). In contrast, in 3ne4 a groove at the
lower pole of the cavity entrance becomes continuous with it (top
right panel, green ellipse). An innermost hydrophobic (Fig. 3, yellow)
chamber shows similar topology between 1qlp and 3ne4, as do the
hydrogen-bond donor (blue) characteristics in the conserved core
region.
The hD–s2A turn in 2qug more closely resembles that seen in 3ne4
than the same region in 1qlp (Fig. 2b). However, this feature alone
does not appear to entirely dictate the overall cavity characteristics
assessed by SiteMap. Thus, while the allosteric cavity in 2qug displays
a truncated upper channel relative to 1qlp, it does not become
continuous with a channel at its lower pole. Moreover, the central
region of the hydrophobic chamber seen in the other structures is lost
structural communications
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Table 2
Cavity characteristics as measured or calculated by the program SiteMap for the cavity flanking -sheet A.
SiteMap output values are given for volume (Vol.), exposure (Exp.), van der Waals contacts (Contact), hydrophobicity (Phob.), hydrophilicity (Phil.) and the weighted balance of these
characteristics (Bal.) and also for hydrogen-bond donor/acceptor ratio (Don/Acc). Overall scores and those for the general ligand (SiteScore) and drug-like compound (Dscore) binding
characteristics are also shown. ‘Tight binders’ refers to values derived from observed correlation with or deliberate calibration against a database of binding sites and ligand interactions
characterized in vitro (Halgren, 2009). N/C, not calibrated by these studies.
Structure
Size (No. of
site points)
Vol.
(A˚3) Exp. Enc. Contact Phob. Phil. Bal. Don/Acc SiteScore Dscore
1qlp 123 252 0.606 0.709 0.908 0.713 1.033 0.691 0.714 1.009 1.029
2qug 78 183 0.639 0.703 0.905 0.557 0.943 0.591 0.967 0.937 0.945
3ne4 90 162 0.583 0.726 0.861 1.028 0.843 1.219 1.056 1.019 1.052
‘Tight binders’ N/C N/C 0.49 0.78 Mean 1.0 Mean 1.0 Mean 1.0 Mean 1.6 N/C 0.8 Sub-mM Kd correlates with 1.01
in 2qug, dividing it. 2qug maintains similar hydrogen-bond acceptor
characteristics of those cavity regions that are shared with the other
two structures. However, the hydrogen-bond donor characteristics in
the 2qug cavity are more concentrated within a narrower distribution
than that in either 1qlp or 3ne4. SiteMap also scores sites for a
number of parameters that have been correlated with tight ligand
binding and druggability (i.e. tight binding of drug-like molecules;
Halgren, 2009). These outputs are listed for the cavities assessed in
the three different structures, together with cutoffs and mean values
correlated with observed behaviour (Table 2). The overall scores for
ligand-binding propensities (SiteScore) and drug-like molecule-
binding propensities (Dscore) are also listed. These data are
consistent with the topological observations in Fig. 3 in quantifying
variability around favourable characteristics for drug binding.
Taken together, these findings characterize the cavity flanking
-sheet A as a highly dynamic feature in native 1-antitrypsin. They
indicate that the most stable features are the two hydrophobic
regions that remain in 2qug and the hydrogen-bond donor/acceptor
features immediately contiguous to them. The uppermost of these
regions closely corresponds to the minimal pharmacophore target
region identified by analysis of the 2.2 A˚ resolution structure of
Thr114Phe 1-antitrypsin (Gooptu et al., 2009). Initial fragment or
small-molecule screens targeting this cavity may therefore most
efficiently be directed against these regions. Compounds binding well
here could serve as templates for a diverse range of derivatives.
Different elaborating motifs within the derivative libraries could then
test the alternative hydrogen-bonding environments and commu-
nicating channel topologies identified by our structural comparison.
The use of relatively low-resolution crystal structures as a
supplement to high-resolution structures has been proposed as a
promising strategy for sampling conformational space explored by
drug targets and thus aiding drug design (Furnham et al., 2006). In the
case of the cavity flanking -sheet A, comparison between the 1qlp,
2qug and 3ne4 structures of 1-antitrypsin provides the benefit of
this outcome without the potential inaccuracies of model building
inherent at lower resolutions.
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